CVS Health (CVS) is targeting the earliest point in a customer’s weight-loss drug decision: the first consultation.
On Aug. 5, the company dropped the cash price of a MinuteClinic online weight-loss visit to $29, with no membership and no monthly fee.
That is the lowest sticker price in the retail telehealth market for a GLP-1 evaluation.
CVS also reported a quarter that beat expectations and raised its full-year outlook the same day — but the $29 visit is the detail worth understanding for anyone holding CVS Health or watching the stock.
It shows how CVS plans to grow, and where that growth plan is most exposed.
CVS uses $29 visit to undercut Hims, Ro, and Noom
Digital-first weight-loss platforms such as Hims & Hers, Ro, and Noom typically charge monthly membership or consultation fees that run from about $40 to well over $100.
CVS priced its clinician visit at $29 and removed the recurring fee entirely.
The $29 covers the clinical evaluation by a licensed clinician who can prescribe GLP-1 therapy when it fits. It does not cover lab work or the medication.
That distinction matters for how CVS makes money here, and it points to the real strategy.
How CVS turns a cheap visit into pharmacy revenue
A $29 visit does not make CVS much money on its own. The prescription it leads to does.
CVS runs about 9,000 pharmacies. When a MinuteClinic clinician writes a GLP-1 prescription, CVS can fill it in its own stores for same-day pickup.
GLP-1 drugs are taken monthly for long stretches, so each new patient can become recurring pharmacy revenue.
More Healthcare Stocks:
- JPMorgan resets LLY stock target on drug demand
- Goldman Sachs says one number will move Eli Lilly stock
- UnitedHealth’s earnings comeback hides a risk Wall Street can’t price
Telehealth startups usually route prescriptions to third-party pharmacies. CVS keeps the whole path inside its own network, from the online visit to the counter.
That is the point of the low price. It is a customer-acquisition tool for the pharmacy business, not a profit center by itself.
The Eli Lilly deal that makes the strategy work
The price cut arrived alongside a new collaboration with Eli Lilly (LLY), and the timing was deliberate.
Through the deal, eligible patients will see transparent pricing for Zepbound and Foundayo, two of Lilly’s weight-loss therapies, inside the CVS Health app, Quartz reported.
Same-day pickup at CVS pharmacies starts in the early fourth quarter of 2026.
Related: UBS strongly resets Lilly stock target
For self-pay patients, CVS pairs the visit with manufacturer savings that bring select GLP-1 medications down to as low as $149 a month with a coupon, according to according to CVS.
Standard cash prices for these drugs often top $1,000.
Lilly has the supply to back this up. Zepbound and Mounjaro generated a combined $14.9 billion last quarter, Benzinga reported.
CVS is positioning itself as the cheapest starting point into that demand.
Why the quarter was strong but the stock still fell
CVS delivered a strong quarter and the market still sold the stock. Both facts are true, and they explain each other.
The company posted adjusted earnings of $2.58 a share, upmore than 40% from a year earlier, on revenue of $106.1 billion, CNBC reported.
Health Services revenue grew 11.5% to nearly $52 billion.
CVS also raised full-year adjusted earnings guidance to $7.90 to $8.10 a share, up from $7.30 to $7.50.
However, shares still fell more than 6% in morning trading.
The trigger was CVS management’s warning about membership declines at Caremark, its pharmacy benefit manager, CNBC noted
So investors got a beat on earnings and a caution flag on future PBM volume in the same report. The weight-loss push does not fix that concern.
What CVS investors should watch next
The $29 offer only pays off if a few things go right.
Here is what needs to happen for the strategy to add real value:
GLP-1 read-through for CVS
- Enough $29 visits convert into filled prescriptions inside CVS pharmacies
- Lilly’s supply keeps up so patients can actually get the drug they were prescribed
- Caremark membership pressure does not erase the pharmacy gains
Supply is the biggest risk. Demand for brand-name GLP-1 drugs has surpassed production, and a customer who pays $29 and cannot get the prescription is a lost customer.
There is also a broader question. CVS still faces scrutiny of its PBM business and cost pressure inside its Aetna insurance unit.
That is why the stock reaction stayed cautious even after a raise.
The bottom line for CVS stock
The $29 visit fee makes CVS the price leader at the entry point of the fastest-growing category in consumer healthcare.
Paired with the Eli Lilly deal and 9,000 pharmacies, it gives CVS a direct, low-cost path to capture GLP-1 patients before rivals do.
It does not solve the Caremark membership worry or the Aetna cost pressure that weighed on the stock this week.
For investors, watch how many of those cheap visits turn into filled prescriptions over the next two quarters.
Also, size any position to your own risk tolerance, because even a strong quarter did not stop this stock from falling.
Related: UnitedHealth CFO sends stark warning after earnings